Risk of vascular disease in patients with multiple sclerosis: A review

Neurological Research

Volumn 34, Issue 8, 2012, Pages 746-753

  Christiansen, Christian Fynbo ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Comorbidity; Multiple sclerosis; Review; Risk; Vascular disease

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; PREVALENCE; RISK ASSESSMENT; STROKE; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

COMORBIDITY; CORONARY ARTERY DISEASE; HUMANS; MULTIPLE SCLEROSIS; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84866240747     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000051     Document Type: Article

References (70)

1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520-532.
2. D'haeseleer M, Cambron M, Vanopdenbosch L, de Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10:657-666.
3. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010;9:830-834.
4. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001;56:1319-1324.
5. Sheremata WA, Jy W, Horstman LL, Arce M, Ahn YS. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation. 2008;5:27.
6. Aksungar FB, Topkaya AE, Yildiz Z, Sahin S, Turk U. Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J Clin Neurosci. 2008;15:393-397.
7. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
8. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991;99:557-561.
9. Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci. 2005;26:334-339.
10. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61:504-513.
11. Paltamaa J, Sarasoja T, Wikstrom J, Malkia E. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med. 2006;38:339-345.
12. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H, et al. Cigarette smoking and the progression of multiple sclerosis. Brain. 2005;128:1461-1465.
13. Friend KB, Mernoff ST, Block P, Reeve G. Smoking rates and smoking cessation among individuals with multiple sclerosis. Disabil Rehabil. 2006;28:1135-1141.
14. Nielsen NM, Westergaard T, Frisch M, Rostgaard K, Wohlfahrt J, Koch-Henriksen N, et al. Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch Neurol. 2006;63:1001-1004.
15. McGreevy C, Williams D. New insights about vitamin d and cardiovascular disease: a narrative review. Ann Intern Med. 2011;155:820-826.
16. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
17. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357-363.
18. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology. 1991;41:1193-1196.
19. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998;65:56-59.
20. Hirst C, Swingler R, Compston DA, Ben-Shlomo Y, Robertson NP. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry. 2008;79:1016-1021.
21. Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology. 2008;30:234-238.
22. Christiansen CF, Christensen S, Farkas DK, Miret M, Sorensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010;35:267-274.
23. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010;17:1215-1219.
24. Fleming ST, Blake RL, Jr. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol. 1994;47:1127-1132.
25. Lindegard B. Diseases associated with multiple sclerosis and epilepsy. A population cohort study of 159,200 middle-aged, urban, native Swedes observed over 10 years (1970-79). Acta Neurol Scand. 1985;71:267-277.
26. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379:244-249.
27. Christensen S, Farkas DK, Pedersen L, Miret M, Christiansen CF, Sørensen HT. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology. 2012;38:76-83.
28. Kaufman J, Khatri BO, Riendl P. Are patients with multiple sclerosis protected from thrombophlebitis and pulmonary embolism? Chest. 1988;94:998-1001.
29. Arpaia G, Bavera PM, Caputo D, Mendozzi L, Cavarretta R, Agus GB, et al. Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: a prospective study. Thromb Res. 2010;125:315-317.
30. Mason K, Thygesen LC, Stenager E, Bronnum-Hansen H, Koch-Henriksen N. Evaluating the use and limitations of the Danish National Patient Register in register-based research using an example of multiple sclerosis. Acta Neurol Scand. 2012;125:213-217.
31. Norgaard M, Jacobsen J, Gradus J, Lash TL, Sorensen HT. Problems with onset of multiple sclerosis based on hospital discharge data. Pharmacoepidemiol Drug Saf. 2007;16:s220-s221.
32. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72:117-124.
33. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology. 2007;28:150-154.
34. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010;63:223-228.
35. Johnsen SP, Overvad K, Sorensen HT, Tjonneland A, Husted SE. Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol. 2002;55:602-607.
36. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56:124-130.
37. Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health. 1992;82:243-248.
38. Goldstein LB. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke. 1998;29:1602-1604.
39. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
40. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-952.
41. Minagar A, Jy W, Jimenez JJ, Alexander JS. Multiple sclerosis as a vascular disease. Neurol Res. 2006;28:230-235.
42. Alexander JS, Zivadinov R, Maghzi AH, Ganta VC, Harris MK, Minagar A. Multiple sclerosis and cerebral endothelial dysfunction: mechanisms. Pathophysiology. 2011;18:3-12.
43. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, Sasaki M, et al. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult Scler. 2003;9:235-238.
44. Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, et al. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 2003;10:299-307.
45. Jy W, Minagar A, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front Biosci. 2004;9:3137-3144.
46. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-1509.
47. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79:57-68.
48. Stosic M, Ambrus J, Garg N, Weinstock-Guttman B, Ramanathan M, Kalman B, et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol. 2010;257:63-71.
49. Miesbach W. Neurologic symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Hemost. 2008;34:286-289.
50. Ferreira S, D'Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;44:434-442.
51. Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C Jr, Ahn YS, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7:36.
52. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998-1005.
53. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993-1997.
54. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation. 2010;7:10.
55. Sternberg Z, Drake A, Sternberg DS, Benedict RH, Li F, Hojnacki D et al. Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis. J Clin Immunol. 2012;32(3):497-504.
56. Norgaard M, Nielsen RB, Jacobsen JB, Gradus JL, Stenager E, Koch-Henriksen N, et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol. 2011;174:945-948.
57. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol. 2007;61:288-299.
58. Massa J, O'Reilly E, Munger KL, Delorenze GN, Ascherio A. Serum uric acid and risk of multiple sclerosis. J Neurol. 2009;256:1643-1648.
59. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503-1507.
60. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE. 2011;6:e16149.
61. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154:69-74.
62. Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil. 2003;84:1823-1830.
63. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sorensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169:1677-1683.
64. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboem-bolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167:935-943.
65. Le PE, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011;17:867-875.
66. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150.
67. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
68. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339-347.
69. Schwarz A, Korporal M, Hosch W, Max R, Wildemann B. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology. 2010;74:2022-2024.
70. Rosso C, Remy P, Creange A, Brugieres P, Cesaro P, Hosseini H. Diffusion-weighted MR imaging characteristics of an acute strokelike form of multiple sclerosis. AJNR Am J Neuroradiol. 2006;27:1006-1008.